- Condition: Type 2 Diabetes Mellitus
Intervention: Behavioral: Lifestyle Counselling
Sponsors: University of Manitoba; University of Manitoba; Manitoba Institute of Child Health
Not yet recruiting - verified May 2012 - Condition: Hyperlipidemia
Intervention: Drug: Sitagliptin
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Merck Frosst Canada Ltd.
Not yet recruiting - verified April 2012 - Condition: Prediabetes
Intervention: Behavioral: Lifestyle changes
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified April 2012 - Condition: Type 1 Diabetes
Intervention: Device: Pump suspension
Sponsors: In Home Closed Loop Study Group; In Home Closed Loop Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2012 - Condition: Gestational Diabetes Mellitus
Interventions: Other: Low GI diet; Other: Standard Care
Sponsors: University of Toronto; University of Toronto; Canadian Diabetes Association; Canadian Institutes of Health Research (CIHR); Canadian Foundation for Dietetic Research (CFDR)
Recruiting - verified April 2012 - Conditions: Heart Failure; Type 2 Diabetes; Glucose Intolerance
Interventions: Drug: Eplerenone; Drug: Spironolactone
Sponsors: Montreal Heart Institute; Montreal Heart Institute; Pfizer
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Statin; Drug: Ace Inhibitor; Drug: Placebo; Drug: Combination therapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Juvenile Diabetes Research Foundation; Diabetes UK; British Heart Foundation; Pfizer; The University of Western Australia; The Hospital for Sick Children; University of Oxford; St Thomas' Hospital, London
Recruiting - verified April 2012 - Conditions: Diabetes Mellitus Type 2; Hypertension
Interventions: Dietary Supplement: Combined Rg3-enriched Korean Red Ginseng (panax Ginseng C.A. Meyer) and American Ginseng (panax Quinquefolius).; Dietary Supplement: 100% Natural Wheat Bran
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Canadian Diabetes Association
Recruiting - verified April 2012 - Conditions: Type 2 Diabetes Mellitus; Gestational Diabetes
Interventions: Device: Continuous Glucose Monitoring; Device: Glucose Meter
Sponsors: Lawson Health Research Institute; Dr. Stewart Harris; Juvenile Diabetes Research Foundation
Not yet recruiting - verified April 2012 - Conditions: Hypertension; Hypercholesterolemia; Type II Diabetes; Obesity; Inflammation
Intervention: Other: vegetable
Sponsors: University of Guelph; University of Guelph; Ontario Ministry of Agriculture, Food and Rural Affairs
Not yet recruiting - verified March 2012 - Condition: Hypoglycemia
Interventions: Drug: glucagon; Drug: low dose experimental formulation; Drug: high dose experimental formulation; Drug: Medium dose experimental glucagon formulation
Sponsors: AMG Medical Inc.; AMG Medical Inc.
Recruiting - verified May 2012 - Conditions: Diabetes; Stroke; Obesity
Intervention:
Sponsors: Children's & Women's Health Centre of British Columbia; Children's & Women's Health Centre of British Columbia
Recruiting - verified March 2012 - Conditions: Hypertension; Diabetes; Infants Small for Gestational Age
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; The Physicians' Services Incorporated Foundation
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Behavioral: Nutrition and Exercise Group; Behavioral: Yoga and Stretching Group
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified May 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Mesalamine; Drug: Prednisone; Drug: Corticosteroids followed by mesalamine (Pentasa)
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: PF-04937319 10 mg; Drug: PF-04937319 50 mg; Drug: PF-04937319 100 mg; Drug: Glimepiride
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: linagliptin; Drug: linagliptin medium dose; Drug: metformin placebo; Drug: metformin placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type-1 Diabetes
Intervention: Device: Dual Hormone closed-loop system
Sponsors: Institut de Recherches Cliniques de Montreal; Institut de Recherches Cliniques de Montreal; McGill University Center for Intelligent Machines; Montreal Children's Hospital
Recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Lixisenatide (AVE0010)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus, Type 2; Hypercholesterolemia
Intervention: Other: BeneFlax - 38% secoisolariciresinol diglucoside (SDG)
Sponsors: University of Saskatchewan; University of Saskatchewan; Saskatchewan Health Research Foundation
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Conditions: Type 2 Diabetes; Hypertension
Interventions: Behavioral: Step count prescription; Behavioral: Usual care
Sponsors: McGill University Health Center; McGill University Health Center; Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Gestational Diabetes Mellitus
Intervention:
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Novolin Toronto insulin; Drug: Normal saline
Sponsors: University of Calgary; University of Calgary
Recruiting - verified November 2011 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Prediabetes; Prehypertension
Intervention: Behavioral: Health Coaching
Sponsors: Memorial University of Newfoundland; Marshal Godwin; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin placebo; Drug: linagliptin placebo; Drug: metformin; Drug: placebo metformin; Drug: metformin; Drug: linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus
Intervention: Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Lower Extremity Chronic Ulcers; Diabetes Mellitus
Interventions: Biological: Curexcell; Biological: Sham injection
Sponsors: Macrocure Ltd.; Macrocure Ltd.; Averion International Corporation
Recruiting - verified September 2011 - Condition: Diabetes Prevention
Intervention: Other: FDD program
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Not yet recruiting - verified August 2011 - Conditions: Diabetes Mellitus, Type 2; Hypertension; Dyslipidemias; Cholesterol, LDL; Comorbitdity
Interventions: Other: Facilitation; Other: Passive diffusion (usual implementation strategy)
Sponsors: Fonds de la Recherche en Santé du Québec; Fonds de la Recherche en Santé du Québec; Université de Montréal
Recruiting - verified August 2011 - Condition: Type 2 Diabetes
Intervention: Other: Internet Communication
Sponsors: Endocrine Research Society; Endocrine Research Society
Recruiting - verified October 2011 - Conditions: Diabetes Mellitus; Overweight; Obesity
Intervention: Dietary Supplement: Salba (Salvia hispanica L.)
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Canadian Diabetes Association
Recruiting - verified June 2009 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes Mellitus; High HbA1c Level; Inadequate Glycaemic Control
Interventions: Drug: dapagliflozin; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb
Recruiting - verified May 2012 - Conditions: Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus
Intervention: Device: Home Blood Glucose Telemonitoring System
Sponsors: Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Ontario Ministry of Health and Long Term Care
Recruiting - verified November 2011 - Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes
Intervention: Drug: Liraglutide-metformin vs insulin-metformin
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Diabete Quebec; Radiological Society of North America Research and Education Foundation; Canadian Heads of Academic Radiology-GE Healthcare Development Award
Recruiting - verified July 2011 - Condition: Prediabetes
Interventions: Behavioral: PREPARE education program; Other: standard of care presentation
Sponsors: Brescia University College; Brescia University College
Recruiting - verified July 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: BI 10773
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis B
Interventions: Other: Control Arm; Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified January 2012 - Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified February 2012 - Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified January 2012 - Condition: Type 1 Diabetes
Intervention: Other: Transition Coordinator
Sponsors: University of Western Ontario, Canada; University of Western Ontario, Canada; Juvenile Diabetes Research Foundation
Not yet recruiting - verified March 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Metformin; Drug: Placebo Comparator
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Institutes of Health Research (CIHR); Mount Sinai Hospital, Canada
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI1356 low dose; Drug: placebo; Drug: BI1356 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: Ischemic Heart Disease; Heart Failure; Chronic Kidney Disease; Diabetes; Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: iCDM
Sponsors: Simon Fraser University; Simon Fraser University; Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health Research
Recruiting - verified April 2011 - Condition: Diabetes
Interventions: Behavioral: Peer Modeling; Behavioral: Control
Sponsors: University of Western Ontario, Canada; University of Western Ontario, Canada
Recruiting - verified June 2011 - Condition: Type 2 Diabetes
Intervention: Drug: Insulin glargine
Sponsors: University of Alberta; University of Alberta; Sanofi-Aventis
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Placebo
Sponsors: Laval University; Laval University; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Procedure: Point-of-care "finger-poke" HbA1c determination.; Procedure: HbA1c blood test; Procedure: HbA1c finger poke test; Procedure: Blood test; Procedure: Blood test
Sponsors: University of British Columbia; University of British Columbia; Vancouver General Hospital
Recruiting - verified April 2012 - Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Device: Simultaneous RT-CGM and Pump Initiation; Device: Delayed Initiation of RT-CGM
Sponsors: Children's Hospital of Eastern Ontario; Children's Hospital of Eastern Ontario; JDRF Canadian Clinical Trial Network
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Macular Edema Following Cataract Surgery
Interventions: Drug: Trientine Hydrochloride; Other: For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: Diabetic Foot Ulcers
Interventions: Device: Epiflo; Other: Moist Wound Therapy
Sponsors: Ogenix Corporation; Ogenix Corporation
Recruiting - verified December 2011 - Conditions: Healthy; Obesity
Interventions: Behavioral: 2 servings of dairy/day and exercise counselling; Behavioral: 4 servings of dairy/day and exercise counselling
Sponsors: McGill University; McGill University; Dairy Farmers of Canada
Recruiting - verified March 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Liraglutide; Drug: placebo
Sponsors: Mount Sinai Hospital, Canada; Mount Sinai Hospital, Canada; Novo Nordisk
Recruiting - verified August 2011 - Conditions: Acute Graft Rejection; Diabetes
Interventions: Drug: Tacrolimus; Drug: Tacrolimus
Sponsors: University of British Columbia; University of British Columbia; Astellas Pharma Canada, Inc.
Not yet recruiting - verified October 2011 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Type 2 Diabetes; Nonalcoholic Steatohepatitis
Interventions: Drug: sitagliptin; Drug: placebo
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; PSI Foundation inc
Recruiting - verified June 2011 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Obesity; Child
Interventions: Behavioral: Cognitive Behavioural Therapy (CBT); Behavioral: Psycho-Education Program (PEP)
Sponsors: University of Alberta; University of Alberta; Alberta Health Services; Canadian Institutes of Health Research (CIHR)
Recruiting - verified December 2011 - Condition: Cystic Fibrosis
Interventions: Drug: Sitagliptin; Drug: Placebo
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified December 2011 - Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011 - Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Oxidative Stress; Inflammation; Aging; Dementia; Pain
Intervention: Dietary Supplement: secoisolariciresinol diglucoside
Sponsors: University of Saskatchewan; University of Saskatchewan; Saskatchewan Health Research Foundation
Recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Gestational Diabetes Mellitus
Interventions: Drug: Insulin; Drug: Metformin, glyburide and insulin
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Fonds de la Recherche en Santé du Québec
Recruiting - verified November 2011 - Condition: Diabetes
Intervention: Procedure: Lispro insulin
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Diabetic Retinopathy
Interventions: Drug: Trientine Hydrochloride; Drug: Oral placebo capsules
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified June 2011 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Intervention: Device: Insulin Pump (Medtronic Minimed Paradigm® VEO)
Sponsors: Medtronic; Medtronic
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Other: Remote Blood Glucose Monitoring; Other: Continuous Glucose Monitoring; Other: SMBG; Other: SMBG With Knowledge
Sponsors: Endocrine Research Society; Endocrine Research Society
Recruiting - verified August 2010 - Conditions: Minimal Change Disease (MCD); Membranous Nephropathy; Glomerulosclerosis, Focal Segmental
Intervention:
Sponsors: University of Michigan; University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The NephCure Foundation
Recruiting - verified March 2012 - Conditions: Glaucoma; Optic Neuropathy; Fibrosis
Interventions: Drug: Bevacizumab; Drug: Control
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Glaucoma Research Society of Canada
Recruiting - verified July 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Conditions: Cystic Fibrosis; Pancreatic Insufficiency
Interventions: Procedure: Abdominal Ultrasound; Other: Sample collection procedures
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Cystic Fibrosis Foundation
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetic Macular Edema
Interventions: Drug: ranibizumab + laser photocoagulation; Drug: ranibizumab; Procedure: laser photocoagulation
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Liver Transplant Recipient
Interventions: Drug: Tacrolimus; Drug: Tacrolimus + everolimus; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsors: Andromeda Biotech Ltd.; Andromeda Biotech Ltd.
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Postmenopause; Overweight
Interventions: Behavioral: Placebo + exercise; Dietary Supplement: Phytoestrogens without exercise; Other: Phytoestrogens + exercise; Other: Placebo without exercise
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Institutes of Health Research (CIHR); Centre de recherche sur le vieillissement du CSSS-IUGS
Recruiting - verified June 2010 - Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified February 2012 - Condition: Gestational Diabetes Mellitus
Intervention: Procedure: 50 g oral glucose challenge test - 75 g oral glucose tolerance test
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Diabetes Association
Recruiting - verified November 2011 - Condition: Diabetic Neuropathy
Intervention: Procedure: Nerve conduction study and Ultrasound of the PTN
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified November 2011 - Conditions: Diabetes Mellitus, Type 2; Atherosclerosis; Prediabetic State
Interventions: Drug: ACZ885 (Canakinumab); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetic Polyneuropathy
Intervention: Procedure: Surgery
Sponsors: Timothy J. Best Medicine Professional Corporation; Timothy J. Best Medicine Professional Corporation; The Physicians' Services Incorporated Foundation
Recruiting - verified December 2011 - Condition: Obesity
Intervention: Behavioral: 2-day preceptorship on obesity management
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Institutes of Health Research (CIHR)
Recruiting - verified February 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Conditions: Gestational Diabetes Mellitus; Type 2 Diabetes
Intervention: Procedure: Oral glucose tolerance test
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke
Recruiting - verified November 2011 - Condition: Glaucoma
Interventions: Drug: ranibizumab; Procedure: standard care
Sponsors: Maisonneuve-Rosemont Hospital; Maisonneuve-Rosemont Hospital; Novartis
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Intervention: Drug: Detemir or Glargine
Sponsors: Institut de Recherches Cliniques de Montreal; Institut de Recherches Cliniques de Montreal; Novo Nordisk; McMaster University
Recruiting - verified June 2011 - Conditions: Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Procedure: islet cell transplant; Other: Medical therapy
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Conditions: Cardiovascular; Diabetes; Orthostatic Hypotension; Type 2 Diabetes
Intervention: Behavioral: Home-based walking program (Aerobic Exercise)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Adalimumab; Drug: Lisinopril, losartan, and atorvastatin; Drug: galactose
Sponsors: New York University School of Medicine; New York University School of Medicine; University of Michigan; The Cleveland Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Myocardial Injury
Interventions: Drug: Propofol; Drug: Propofol
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified November 2011 - Condition: Diabetes Mellitus
Interventions: Drug: placebo; Drug: exenatide
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Other: multidisciplinary approach; Other: multifactorial approach - for enhanced care group; Other: reflects current patterns of care
Sponsors: University of Alberta; University of Alberta; Alberta Heritage Foundation for Medical Research
Recruiting - verified November 2011 - Conditions: Diabetes Mellitus; Chronic Ulcers of the Lower Limb
Interventions: Procedure: Hyperbaric Oxygen Therapy; Procedure: Placebo Hyperbaric Oxygen Chamber
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton; Judy Dan Research and Treatment Centre Ontario Wound Care Inc; University Health Network, Toronto
Recruiting - verified July 2011 - Conditions: Type 1 Diabetes; Pregnancy
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified September 2011 - Conditions: Obesity; Gestational Diabetes; Type 2 Diabetes
Intervention: Behavioral: Exercise and dietary education
Sponsors: University of Manitoba; University of Manitoba; The Lawson Foundation
Recruiting - verified August 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Islet transplant; Drug: Belatacept; Drug: Basiliximab; Drug: Mycophenolate Mofetil
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Conditions: Type 2 Diabetes; Peripheral Vascular Disease
Interventions: Behavioral: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician; Behavioral: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team; Behavioral: Subjects without diabetes will have their blood glucose levels monitored while in the hospital
Sponsors: University of British Columbia; University of British Columbia; Novo Nordisk
Recruiting - verified December 2011 - Condition: Type 2 Diabetes
Interventions: Drug: glyburide; Drug: GlucoNorm
Sponsors: University of British Columbia; University of British Columbia; Novo Nordisk
Recruiting - verified February 2012 - Condition: Type 2 Diabetes
Intervention: Drug: Sitagliptin 100 mg
Sponsors: University of British Columbia; University of British Columbia; Merck Frosst Canada Ltd.
Recruiting - verified February 2012 - Condition: Malnourished Children With Cancer
Interventions: Drug: Megstrol Acetate; Other: Placebo
Sponsors: University of British Columbia; University of British Columbia; University of Alberta
Recruiting - verified October 2011 - Condition: Type 2 Diabetes
Interventions: Procedure: laparoscopic gastric bypass surgery; Procedure: laparoscopic adjustable gastric banding; Procedure: Intensive Medical Management
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Diabetes
Intervention: Behavioral: Resistance Exercise
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified May 2012 - Conditions: Cardiovascular; Diabetic
Interventions: Behavioral: Aerobic Exercise and Strength Exercise; Behavioral: Strength training
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified December 2011 - Condition: Schizophrenia
Interventions: Drug: Aripiprazole; Drug: Risperidone; Drug: Clozapine
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; National Institute of Mental Health (NIMH)
Recruiting - verified January 2012 - Condition: Functional Dyspepsia
Interventions: Drug: Amitriptyline; Drug: escitalopram; Drug: placebo
Sponsors: Mayo Clinic; Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Conditions: Kidney Diseases; Heart Diseases; Diabetes Mellitus
Intervention: Procedure: The Combined Cardiac Kidney Diabetes Care Clinic
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012 - Condition: Diabetes
Interventions: Procedure: High Hemoglobin Concentration; Procedure: Low Hemoglobin Concentration
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011 - Conditions: Biliary Atresia; Cholestasis
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
 |
Join Clinical Trials for Diabetes in Canada |
